Comparison
Abacavir Hypersensitivity C5768819 vs 2 Aminoadipic 2 Oxoadipic Aciduria C1859817
Clinical comparison between Abacavir Hypersensitivity and 2 Aminoadipic 2 Oxoadipic Aciduria for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
A metabolic disorder affecting how the body breaks down certain amino acids. It can cause developmental delays and neurological problems. Treatment includes dietary changes and supportive therapies.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
0-18
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
metabolic
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
metabolic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 2-aminoadipic-2-oxoadipic-aciduria-C1859817 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 2 Aminoadipic 2 Oxoadipic Aciduria C1859817 | Discriminating power |
|---|---|---|---|
| Timing | Usually after starting abacavir; timing is variable. | Often recognized from birth through age 18. | High |
| Course | Acute reaction that may worsen if exposure continues. | Chronic metabolic condition with variable neurologic effects. | High |
| Main features | May involve fever, rash, gastrointestinal or respiratory symptoms. | May include developmental delay or neurologic problems; some people are mildly affected. | Moderate |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
New multisystem illness after abacavir exposure
Drug timing and immune features favor hypersensitivity over a metabolic disorder.
High
Positive HLA-B*5701 risk assessment
This genetic risk marker is relevant to abacavir reaction risk, not aminoaciduria.
High
Symptoms improve after supervised drug withdrawal
Resolution after stopping abacavir supports a drug reaction, but rechallenge is unsafe.
Moderate
Choose 2 Aminoadipic 2 Oxoadipic Aciduria C1859817 when
Childhood developmental or neurologic concerns
A chronic metabolic disorder is more plausible than an acute drug reaction.
Moderate
Abnormal urine organic-acid pattern
Elevated relevant metabolites suggest the metabolic condition, pending specialist confirmation.
Moderate
No abacavir exposure
Hypersensitivity requires exposure to abacavir.
High
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 2 Aminoadipic 2 Oxoadipic Aciduria C1859817 | Interpretation |
|---|---|---|---|
| HLA-B*5701 testing | Used before abacavir to identify higher reaction risk. | Not diagnostic for this metabolic disorder. | A risk marker is not proof of an active reaction. |
| Urine organic acids | No characteristic aminoadipic-acid pattern expected. | May show elevated 2-aminoadipic and 2-oxoadipic acids. | Abnormal metabolites require metabolic-specialist interpretation. |
| Clinical exposure history | Recent abacavir use is essential context. | History is independent of abacavir exposure. | Exposure history strongly separates the conditions. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Often improves after abacavir is stopped, but severe reactions can occur.
- Factors
- Early recognition, permanent avoidance, and no rechallenge.
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
- Outcome
- Chronic course with outcomes ranging from mild effects to developmental or neurologic problems.
- Factors
- Phenotype, metabolic control, and supportive care; exact prognosis is not established here.
Time frame: Hours to weeks for the drug reaction; lifelong for the metabolic disorder.
Exposure history, genetic risk, metabolite results, and clinical course.
Complications comparison
| Complication | Presentation |
|---|---|
| Severe systemic reaction | Can become serious, especially with continued exposure or rechallenge. Not a typical feature of the metabolic disorder. Urgent assessment is needed for suspected hypersensitivity. |
| Neurologic impairment | Not the defining long-term complication. Developmental or neurologic problems may occur, with variable severity. Severity is not predictable from the supplied data. |
| Need for ongoing support | Mainly avoidance of abacavir after recovery. May require dietary management and supportive therapies. Specific regimens must be individualized. |
Patient education highlights
- HighDo not restart abacavir
Suspected hypersensitivity requires urgent care; restarting abacavir can be dangerous.
- HighSeparate conditions
A drug reaction and an inherited metabolic disorder need different evaluation and follow-up.
- MediumSpecialist review
Abnormal tests or developmental concerns should be interpreted by the appropriate clinician.